DOI: 10.25881/BPNMSC.2019.61.17.001

Authors

Shevchenko Yu.L., Borshchev G.G., Ulbashev D.S., Vahromeeva M.N., Vahrameeva A.YU.

Pirogov National Medical and Surgical Center, Clinic of Thoracic and Cardiovascular Surgery St. George’s, Moscow

Abstract

The article analyzes the of methods and studies assessing the viability and functional reserves of the myocardium in patients with coronary heart disease. The need to perform a comprehensive examination to plan and predict myocardial revascularization by coronary artery stenting or coronary artery bypass grafting. The advantage of using load echocardiography to determine myocardial contractile reserve, scintigraphy to detect myocardial perfusion and integrity of cell membranes of cardiomyocytes and PET to assess the metabolic activity of the myocardium was demonstrated.

Keywords: myocardium, coronary disease, scintigraphy, echocardiography, positron emission tomography.

References

1. Eckardt R, Kjeldsen BJ, Johansen A, et al. Can preoperative myocardial perfusion scintigraphy predict changes in left ventricular perfusion and function after coronary artery bypass graft surgery? Interact Cardiovasc Thorac Surg. 2012;14(6): 779-784. doi: 10.1093/icvts/ivs099.

2. Wang Li, Lu MJ, Feng L, Wang J. Relantionship of myocardial hibernation, scar, and angiographic collateral flow in ischemic cardiomyopathy with coronary chronic total occlusion. Journal of Nuclear Cardiology. 2018;29(3):134-146. doi: 10.1007/ s12350-018-1241-8.

3. Opie LH. The heart:physiology and metabolism. New-York : Raven Pr, Subsequent edition; 1990.

4. Kapelko VI. Narusheniya energoobrazovaniya v kletkah serdechnoj myshcy: prichiny i sledstviya. Sorosovskij obrazovatel’nyj zhurnal. 2000;(5):14-20. (In Russ).

5. Shilov AM. Nekotorye osobennosti patogeneza ishemicheskoj bolezni serdca. Russkij medicinskij zhurnal. 2007; 15(9):686-692. (In Russ).

6. Camici P, Ferrannini E, Opie LH. Myocardial metabolism in ischemic heart disease: basic principles and application to imaging by positron emission tomography. Prog. Cardiovasc. Dis. 1989; 32:217-238. doi: 10.1016/0033-0620(89) 90027-3.

7. Vander Vusse GJ, van Bilsen M, Glatz JF. Cardiac fatty acid uptake and transport in health and disease. Cardiovasc. Res. 2000; 45:279-293. doi: 10.1016/s0008-6363(99)00263-1.

8. Bing RJ, Siegel A, Ungar I, Gilbert M. Metabolism of the Human Heart: II. Studies on Fat, Ketone and Amino Acid Metabolism. American Journal of Medicine. 1954;16:504-515. doi: 10.1016/0002-9343(54)90365-4.

9. Yakovleva LN. Osobye sostoyaniya miokarda pri ishemii. Medicine of Ukraine. 2010;218(2):43-50. (In Russ).

10. Bogaert J. Comprehensive Evaluation of Hibernating Myocardium: Use of Noninvasive Imaging. Journal of Thoracic Imaging. 2014:29(3):134-146. doi: 10.1097/RTI.0000000000000069.

11. Braunwald E, Kloner RA. The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation. 1982:66(6):1146-1149. doi: 10.1161/01.cir.66.6.1146.

12. Heyndrickx GR, Baig H, Nellens P. Depression of regional blood flow and wall thickening after brief coronary occlusions. Am. J. Physiol. 1978;234:653-659. doi: 10.1152/ajpheart.1978.234.6.h653.

13. Paul A., Hasegawa S, Yoshioka J. Characteristics ofregional myocardial stunning after exercise in gated myocardial SPECT. J. Nucl. Cardiol. 2002;9:388-394. doi: 10.1067/mnc.2002.123269.

14. Opie LH. Chronic stunning: a new switch in thought. Basic Res. Cardiol. 1995;75: 303-304. doi: 10.1007/978-3-642-53793-6_35.

15. Piot C, Croisille P, Staat P. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N. Engl. J. Med. 2008;359:473-481. doi: 10.1016/s0145-4145 (09)79501-2.

16. Nemkov AS, YAkovlev DA, Borisov AI, Belyj SA. Gibernaciya i stanning - osobye formy sushchestvovaniya miokarda pri ishemicheskoj bolezni serdca. CHast’ 2: Stanning. Regionarnoe krovoobrashchenie i mikrocirkulyaciya. 2011;3:4-9. (In Russ).

17. Kloner RA, Forman MB, Gibbons RJ. Impact of time to therapy and reperfusion modality on efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trail. Eur. Heart. J. 2006;27:2400-2405. doi: 10.1093/eurheartj/ehl094.

18. Patel JA, Gharak SB. Pexelizumab and its role in the treatment of myocardial infarction and coronary artery bypass graft surgery:a review. Recent Patients . Cardiovasc. Drug. Discov. 2008;3:145-152. doi: 10.2174/157489008784705322.

19. Garcia SC, Pomblum V, Gams E. Independency ofmyocardial stunning of endothelial stunning? Basic Res. Cardiol. 2007;102:359-367. doi: 10.1007/s00395-007-0657-0.

20. Opie LH. The multifarious spectrum of ischemia left ventricular disfunction: relevance of new ischemic syndromes. Journal of Molecular and Cellular Cardiology. 1996;28:2403-2414. doi: 10.1006/jmcc.1996.0233.

21. Burgdorf C, Richardt D, Kurz T. Adenosine inhibits norepinephrine release in the postischemoc rat heart: the mechanism of neuronal stunning. Cardiovasc. Res. 2001;49:713-720. doi: 10.1016/s0008-6363(00)00309-6.

22. Meyer K, Klocke RC, Schipkeet JD. Ca(2+) sensitizer superior to catecholamine during myocardial stunning? Eur. J. Cardiothorac. Surg. 2008;34:326-331. doi: 10.1016/j.ejcts.2008.04.042.

23. Bolli R, Marbán E. Molecular and Cellular Mechanisms of Myocardial Stunning. Physiological Reviews. 1999;79(2):609-634. doi: 10.1016/0022-2828(92)91076-h.

24. Burwell LS, Brookes PS. Mitochondria as a target for the cardioprotective effects of nitric oxide in ischemia-reperfusion injury. Antioxid Redox Signal. 2008;10:579-599. doi: 10.1089/ars.2007.1845.

25. Piper HM, Abdallah Y, Kasseckert S. Sarcoplasmic reticulum-mitochondrial interaction in the mechanism of acute reperfusion injury. Cardiovasc. Res. 2008;77:234-236. doi: 10.1093/cvr/cvm066.

26. Bolli R. Mechanism of myocardial “stunning”. Circulation. 1990;82:723-738. doi: 10.1161/01.cir.82.3.723.

27. Heusch G, Sipido K. Myocardial hibernation: a double-edge sword. Circ. Res. 2004;94(8):1005-1007.

28. Rahimtoola SH. A perspective on three large multicenter randomized clinical trials of coronary bypass surgery for chronic stable angina. Circulation. 1985;72:123-135.

29. Nemkov AS, YAkovlev DA, Borisov AI, Belyj SA. Gibernaciya i stanning - osobye formy sushchestvovaniya miokarda pri ishemicheskoj bolezni serdca. CHast’ 1: Gibernaciya. Regionarnoe krovoobrashchenie i mikrocirkulyaciya. 2011;10 (2):5-12. (In Russ).

30. Bokeriya LA, Aslanidi IP, SHurupova IV, Klyuchnikov IV, Karalkin AV. Vozmozhnosti radionuklidnyh metodov v ocenke zhiznesposobnosti miokarda u bol’nyh ishemicheskoj bolezn’yu serdca. Radiacionnaya onkologiya i yadernaya medicina.2011;2:55-70. (In Russ).

31. Nikiforov VS. Vyyavlenie zhiznesposobnogo miokarda pri ishemicheskoj disfunkcii miokarda: sovremennye vozmozhnosti i prakticheskoe znachenie. Mezhdunarodnyj zhurnal serdca i sosudistyh zabolevanij. 2016;4(12):17-26. (In Russ).

32. Kenzhaev ML, Alyavi AL, Kenzhaev SR, Dadamyanc NG, Rahimova RA, Ortikov MM. Metody diagnostiki zhiznesposobnogo miokarda pri ostrom infarkte miokarda. Vestnik ekstrennoj mediciny. 2018;2:68-74. (In Russ).

33. Horn HR, Teichholz LE, Cohn PF. Augmentation of left ventricular contraction pattern in coronary artery disease by an inotropic catecholamine: the epinephrine ventriculogram. Circulation. 1974;49:1063-1071. doi: 10.1161/01.cir.49.6.1063.

34. Hoffmann R, Altiok E, Nowak B. Strain rate measurement by doppler echocardiography allows improved assessment of myocardial viability inpatients with depressed left ventricular function. J Am Coll Cardiol. 2002;39(3):443-449. doi: 10.1016/s0735-1097(01)01763-6.

35. Schinkel AF, Bax JJ, Poldermans D. Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol. 2007;32:375-410. doi: 10.1016/j.cpcardiol.2007.04.001.

36. Vahromeeva MN, Vahrameeva AYu. Diagnostika gibernirovannogo miokarda s pomoshch’yu sinhronizirovannoj odnofotonnoj emissionnoj tomografii u bol’nyh s postinfarktnymi anevrizmami levogo zheludochka.Vestnik Nacional’nogo mediko-hirurgicheskogo Centra im. N.I. Pirogova. 2018;1(13):108-115. (In Russ).

37. Abdel-Aty H, Zagrosek A, Schulz-Menger J. Delayed enhancement and T2-weighted cardiovascular magnetic resonance imaging differentiate acute from chronic myocardial infarction. Circulation. 2004;109:2411-2416. doi: 10.1161/01.CIR.0000127428. 10985.C6.

38. Wijns W, Vatner SF, Camici PG. Hibernating myocardium. N Engl J Med. 1998;339:173-181. doi: 10.1056/NEJM199807163390307.

39. Allman KC, Shaw LJ, Hachamovitch R. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J. Amer. Coll. Cardiol. 2002;39:1151-1158. doi: 10.1016/s0735-1097(02)01726-6.

40. SHevchenko YUL, Popov LV, Vahromeeva MN, Denisenko-Kankiya EI, Borshchev GG. Otdalennye rezul’taty operacii koronarnogo shuntirovaniya bez iskusstvennogo krovoobrashcheniya u pacientov s ishemicheskoj bolezn’yu serdca i povyshennym hirurgicheskim riskom pri raznom ob”eme revaskulyarizacii. Vestnik Nacional’nogo mediko-hirurgicheskogo Centra im N.I. Pirogova. 2015;3(10):9-13. (In Russ).

41. D’Egidio G, Nichol G, Williams KA. Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation: substudy of the PARR-2 trail. J. Amer. Col. Cardiol. Cardiovasc. Imaging. 2009;2: 1060-1068. doi: 10.1016/j.jcmg.2009.02.017.

42. Slart RH, Bax JJ, van Veldhuisen DJ. Imaging techniques in nuclear cardiology for the assessment of myocardial viability. Int. J. Cardiovasc. Imaging. 2006;22:63-80. doi: 10.1007/s10554-005-7514-8.

43. Zhang X, Liu XJ, Wu Q. Clinical outcome of patients with previous myocardial infarction and left ventricular dysfunction assessed with myocardial 99mTc-MIBI SPECT and 18F-FDG PET. J. Nucl. Med. 2001;42:1116-1173.

44. Mule J, Bax JJ, Zingone B. The beneficial effect of revascularization on jeopardized myocardium: reverse remodeling and improved long-term prognosis. Eur. J. Cardiothorac. Surg. 2002;22:426-430. doi: 10.1016/s1010-7940(02)00359-7.

45. Underwood S. Imaging techniques in the assessment of myocardial hibernation. European Journal of Nuclear Medicine and Molecular Imaging. 2004;8(31):1209. doi: 10.1016/j.ehj.2004.03.012.

46. Slart RH, Bax JJ, van Veldhuisen DJ, Vanderwall E, Dierckx R, Deboer J, Jager P. Prediction of functional recovery after revascularization in patients with coronary artery disease and left ventricular dysfunction by gated FDG-PET. Journal of Nuclear Cardiology. 2006; 2(13):210-219. doi: 10.1007/bf02971245.

47. Pagano D, Townend JN, Littler WA. Coronary artery bypass sugary as treatment for ischemic heart failure: the predictive value of viability assessment with quantitative positron emission tomography for symptomatic and functional outcome. J. Thorac Cardiovasc. Surg. 1998; 115:791-799.

48. Verani MS, Taillefer R, Iskandrian AE. 123I–IPPA SPECT for the prediction of enhanced left ventricular function after coronary bypass graft surgery. Multicenter IPPA Viability Trial Investigators. 123I-iodophenylpentadecanoic acid. J Nucl Med. 2000;8(41):1299-1307.

For citation

Shevchenko Yu.L., Borshchev G.G., Ulbashev D.S., Vahromeeva M.N., Vahrameeva A.YU. Assessment of myocardial viability and functional reserves in patients with chronic coronary artery disease. Bulletin of Pirogov National Medical & Surgical Center. 2019;3(14):4-12. (In Russ.) https://doi.org/10.25881/BPNMSC.2019.61.17.001